Mission GBM
Subscribe
Sign in
Home
Glossary of Terms
Brain Cancer News
Brain Cancer Science Talk
Clinical Trials
FAQs
Goals of Care
Investing in Brain Cancer
Julie's Journey
Meet the Team
Archive
About
Brain Cancer News
Latest
Top
Breaking News: FDA Approves Vorasidenib (Voranigo®)
A great day for Low Grade Astrocytoma and Oligodendroglioma Patients with IDH1/IDH2 Mutations
Aug 6, 2024
•
Scott L. Rakestraw, PhD
7
Share this post
Mission GBM
Breaking News: FDA Approves Vorasidenib (Voranigo®)
Copy link
Facebook
Email
Notes
More
ASCO 2024: Brain Cancer Highlights
A few potential gems begin to sparkle
Jun 20, 2024
•
Scott L. Rakestraw, PhD
2
Share this post
Mission GBM
ASCO 2024: Brain Cancer Highlights
Copy link
Facebook
Email
Notes
More
News: Erasca Reorganizes and Deprioritizes Development of ERAS-801 for rGBM
Yet Another EGFR-targeted Monotherapy Drops Anchor
May 17, 2024
•
Scott L. Rakestraw, PhD
3
Share this post
Mission GBM
News: Erasca Reorganizes and Deprioritizes Development of ERAS-801 for rGBM
Copy link
Facebook
Email
Notes
More
Sam Blackman Speaks from the Heart
A personal account of bringing a new brain cancer medicine to patients
Apr 30, 2024
•
Scott L. Rakestraw, PhD
1
Share this post
Mission GBM
Sam Blackman Speaks from the Heart
Copy link
Facebook
Email
Notes
More
Breaking News: FDA Approves Tovorafenib (Ojemda®) for Pediatric LGG with BRAF Mutations
A Wonderful Day for pLGG patients and their families
Apr 23, 2024
•
Scott L. Rakestraw, PhD
5
Share this post
Mission GBM
Breaking News: FDA Approves Tovorafenib (Ojemda®) for Pediatric LGG with BRAF Mutations
Copy link
Facebook
Email
Notes
More
AACR Brain Cancer Highlights
A tantalizing Phase 1 study of AZD-1390, some potential insights into poor CAR-T efficacy against solid tumors, and disappointing OS performance of…
Apr 11, 2024
•
Scott L. Rakestraw, PhD
2
Share this post
Mission GBM
AACR Brain Cancer Highlights
Copy link
Facebook
Email
Notes
More
Marizomib Fails a Phase 3 Clinical Trial in ndGBM Patients
Big Study. Muddy Biology. Ugh!
Mar 29, 2024
•
Scott L. Rakestraw, PhD
1
Share this post
Mission GBM
Marizomib Fails a Phase 3 Clinical Trial in ndGBM Patients
Copy link
Facebook
Email
Notes
More
Novocure Reports METIS Top Line Clinical Trial Results for Brain Metastases from NSCLC
Promising, but we will wait for the full data presentation
Mar 27, 2024
•
Scott L. Rakestraw, PhD
2
Share this post
Mission GBM
Novocure Reports METIS Top Line Clinical Trial Results for Brain Metastases from NSCLC
Copy link
Facebook
Email
Notes
More
FDA and EMA Accept Vorasidenib Regulatory Submissions for the Treatment of IDH-mutant Diffuse Glioma
News of Enormous Potential for IDH-mutant Glioma Patients
Feb 21, 2024
•
Scott L. Rakestraw, PhD
6
Share this post
Mission GBM
FDA and EMA Accept Vorasidenib Regulatory Submissions for the Treatment of IDH-mutant Diffuse Glioma
Copy link
Facebook
Email
Notes
More
Another EGFRvIII-targeted Program BiTEs the Dust
Same As It Ever Was
Feb 1, 2024
•
Scott L. Rakestraw, PhD
2
Share this post
Mission GBM
Another EGFRvIII-targeted Program BiTEs the Dust
Copy link
Facebook
Email
Notes
More
MimiVax Announces New Investments to Support Clinical Development of SurVaxM in Glioblastoma
Example of a transitional model for financing brain cancer therapeutics development
Jan 10, 2024
•
Scott L. Rakestraw, PhD
2
Share this post
Mission GBM
MimiVax Announces New Investments to Support Clinical Development of SurVaxM in Glioblastoma
Copy link
Facebook
Email
Notes
More
SNO Storm: Phase 3 Results for DCVax-L
Highlights from the Society for Neuro-Oncology (SNO) 2022 Annual Meeting
Nov 18, 2022
•
Scott L. Rakestraw, PhD
5
Share this post
Mission GBM
SNO Storm: Phase 3 Results for DCVax-L
Copy link
Facebook
Email
Notes
More
Share
Copy link
Facebook
Email
Notes
More
This site requires JavaScript to run correctly. Please
turn on JavaScript
or unblock scripts
